Fulltext present in this item

Thumbnail
Fulltext: 88766.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Biomarkers as disease definition: mantle cell lymphoma as an example.
Author(s): Krieken, J.H.J.M. van ; Jansen, C. ; Hebeda, K.M. ; Groenen, P.J.T.A.
Publication year: 2010
Source: Proteomics Clinical Applications, vol. 4, iss. 12, (2010), pp. 922-925
ISSN: 1862-8346
DOI: http://dx.doi.org/10.1002/prca.201000048
Annotation: 1 december 2010
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/88766   https://hdl.handle.net/2066/88766

Display more details
Subject: ONCOL 3: Translational research
Organization: Pathology
Journal title:
Proteomics Clinical Applications
Volume: vol. 4
Issue: iss. 12
Page start: p. 922
Page end: p. 925
Abstract:
The introduction in pathology practice of a new biomarker that is contributing to define a disease requires a series of investigations. Now that new biomarkers are being discovered continuously it is important to learn from successful examples of markers that are presently widely used. In this historical account the steps are described that have led to the use of immunohistochemical staining of tissue samples with an antibody against cyclinD1 to diagnose mantle cell lymphoma. Furthermore, a short outlook is given on the introduction of proteomics as a tool in the diagnosis of lymphoma and the potential route to be taken for introducing this technology into clinical practice.

This item appears in the following Collection(s)

Browse

Statistics